NCT02318329 2024-06-04
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
Five Prime Therapeutics, Inc.
Phase 1 Completed
Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc.
Amgen